Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Q1 2018 Earnings Conference Call - Final Transcript
May 10, 2018 • 08:30 am ET
own very successfully and we will do that if that's the decision that we make. I would say, Tim, as well I think the point that you're getting is I would not rule out Eagle bringing in additional opportunistic products like this because we do have a certain level of talent here.
We're very good at filing patents. I think we're very good at getting around patents. We're very good at coming up with tricky formulations being able to get hard products to the market which we've been doing since the company was in existence. And now you layer on the sales capability and the marketing capability that we have here, there's no reason if we find opportunities like this that we can just easily bring into the company to find additional value for our shareholders. There's no reason to pass up on those opportunities and I think it's likely that we'll continue to announce situations like this where we believe we have an unusual capability of bringing value to the company.
Understood. Thanks for all the questions.
All right. Thank you very much.
Thank you. At this time, we have no further questions. So we'd like to take a moment and thank everybody for joining today's program. Please note this does end today's call and you may disconnect at any time, and have a good day.
Thank you, everybody. I appreciate the time you spent on the call with us. Thank you.